Phase 1 dose-escalation study to evaluate VS-7375 in the U.S., with plans to expand as monotherapy into pancreatic cancer and non-small cell lung cancer cohorts, along with colorectal cancer in combination with cetuximab BOSTON / Jun 24, 2025 / Business Wire / Verastem Oncology...Read more
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing...Read more
Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone Patients with liver...Read more
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company...Read more
MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard...Read more
PDUFA action date set for October 25, 2025 sNDA being reviewed under FDA’s RTOR program Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| argenx | 27.31 5.05 | $568.06 |
| Mettler-Toledo | 21.57 1.85 | $1,185.18 |
| Nektar Therapeutics | 15.25 159.84 | $24.79 |
| Alnylam Pharmaceuticals | 11.87 3.79 | $325.00 |
| GeneDx | 11.19 14.04 | $90.90 |
| Regeneron Pharmaceuticals | 10.35 2.02 | $522.27 |
| Cellectar Biosciences | 9.40 3,157.22 | $9.70 |
| Intuitive | 7.99 1.55 | $523.08 |
| DexCom | 7.74 9.69 | $87.58 |
| Eli Lilly | 7.44 0.97 | $778.08 |
| Stryker | 7.30 1.93 | $386.46 |
| Vertex Pharmaceuticals | 6.73 1.52 | $450.27 |
| Medpace | 6.70 2.17 | $315.28 |
| West Pharmaceutical | 5.98 2.76 | $222.68 |
| IDEXX Laboratories | 5.85 1.12 | $530.50 |
| Krystal Biotech | 5.75 4.17 | $143.67 |
| Chemed | 5.74 1.04 | $557.32 |
| TransMedics | 5.11 4.01 | $132.64 |
| Company | Volume | Last Trade |
|---|---|---|
| OneMedNet | 492,315,808 | $0.68 |
| Healthcare Triangle | 364,289,551 | $0.03 |
| Plus Therapeutics | 119,866,787 | $0.19 |
| Adial Pharmaceuticals | 112,193,991 | $0.23 |
| InMed Pharmaceuticals | 109,244,975 | $3.80 |
| Vor Bio | 97,601,373 | $0.32 |
| iBio | 72,848,151 | $0.74 |
| NuCana | 63,797,884 | $0.09 |
| Senseonics | 49,203,325 | $0.50 |
| Trinity Biotech | 43,223,772 | $0.70 |
| Eyenovia | 41,522,078 | $9.00 |
| Electromedical Technologies | 37,800,000 | $0.00 |
| Nektar Therapeutics | 36,360,460 | $24.79 |
| Moleculin Biotech | 36,233,263 | $0.30 |
| Pfizer | 32,475,299 | $24.30 |
| Oscar Health | 26,371,423 | $19.99 |
| Sangamo Therapeutics | 23,540,900 | $0.51 |
| Recursion | 22,459,245 | $5.22 |
| Incannex Healthcare | 22,113,102 | $0.22 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
